ArticleTurkish journal of anaesthesiology and reanimation2020
Use of Spironolactone in SARS-CoV-2 ARDS Patients.
Article in Turkish journal of anaesthesiology and reanimation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Covid-19 and development of heart failure: mystery and truth.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- To Curb the Progression of Fatal COVID-19 Course-Dream or Reality.Current hypertension reports · 2021Review
- ACE2 Netlas:Frontiers in genetics · 2021Article
- ACE2 Netlas: In-silico functional characterization and drug-gene interactions ofmedRxiv : the preprint server for health sciences · 2020Article
- Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).Medical hypotheses · 2020Article
- Repurposing existing drugs for COVID-19: an endocrinology perspective.BMC endocrine disorders · 2020Article
- Possible Old Drugs for Repositioning in COVID-19 Treatment: Combating Cytokine Storms from Haloperidol to Anti-interleukin Agents.Turkish journal of anaesthesiology and reanimation · 2020Article
- Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19.Frontiers in medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.